ARCUS BIOSCIENCES INC (RCUS)
US03969F1093 - Common Stock
RCUS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. The financial health of RCUS is average, but there are quite some concerns on its profitability. RCUS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RCUS had negative earnings in the past year.
RCUS had a negative operating cash flow in the past year.
In the past 5 years RCUS reported 4 times negative net income.
In multiple years RCUS reported negative operating cash flow during the last 5 years.
1.2 Ratios
RCUS has a Return On Assets of -28.04%. This is in the better half of the industry: RCUS outperforms 74.53% of its industry peers.
Looking at the Return On Equity, with a value of -66.45%, RCUS is in line with its industry, outperforming 58.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.04% | ||
| ROE | -66.45% | ||
| ROIC | N/A |
ROA(3y)-14.86%
ROA(5y)-20.44%
ROE(3y)-33.6%
ROE(5y)-35.4%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RCUS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RCUS has been increased compared to 1 year ago.
The number of shares outstanding for RCUS has been increased compared to 5 years ago.
There is no outstanding debt for RCUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RCUS has an Altman-Z score of 0.05. This is a bad value and indicates that RCUS is not financially healthy and even has some risk of bankruptcy.
RCUS's Altman-Z score of 0.05 is in line compared to the rest of the industry. RCUS outperforms 59.83% of its industry peers.
There is no outstanding debt for RCUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.05 |
ROIC/WACCN/A
WACC9.13%
2.3 Liquidity
RCUS has a Current Ratio of 4.52. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.52, RCUS perfoms like the industry average, outperforming 50.26% of the companies in the same industry.
RCUS has a Quick Ratio of 4.52. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
RCUS has a Quick ratio of 4.52. This is comparable to the rest of the industry: RCUS outperforms 51.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.52 | ||
| Quick Ratio | 4.52 |
3. Growth
3.1 Past
The earnings per share for RCUS have decreased strongly by -11.56% in the last year.
RCUS shows a small growth in Revenue. In the last year, the Revenue has grown by 4.37%.
RCUS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 69.35% yearly.
EPS 1Y (TTM)-11.56%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-16.13%
Revenue 1Y (TTM)4.37%
Revenue growth 3Y14.72%
Revenue growth 5Y69.35%
Revenue growth Q2Q-8.01%
3.2 Future
Based on estimates for the next years, RCUS will show a small growth in Earnings Per Share. The EPS will grow by 7.49% on average per year.
The Revenue is expected to grow by 34.36% on average over the next years. This is a very strong growth
EPS Next Y13.39%
EPS Next 2Y-2.4%
EPS Next 3Y2.75%
EPS Next 5Y7.49%
Revenue Next Year68.29%
Revenue Next 2Y20.95%
Revenue Next 3Y5.04%
Revenue Next 5Y34.36%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
RCUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RCUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.4%
EPS Next 3Y2.75%
5. Dividend
5.1 Amount
RCUS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARCUS BIOSCIENCES INC
NYSE:RCUS (5/8/2024, 2:36:42 PM)
15.297
-0.26 (-1.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.39B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.04% | ||
| ROE | -66.45% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.52 | ||
| Quick Ratio | 4.52 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-11.56%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y13.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.37%
Revenue growth 3Y14.72%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y